The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.af

Thrombotic microangiopathy

Publications

George JN, Morton JM, Liles NW, Nester CM

After the Party's Over.

The New England journal of medicine. 2017;376(1):74-80

Reese JA, Bougie DW, Curtis BR, Terrell DR, Vesely SK, Aster RH, George JN

Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin.

American journal of hematology. 2015;90(5):406-10

Houstoun M, Reichman ME, Graham DJ, Nambiar S, Shamsuddin H, Jones SC, Cao K, Wernecke M, Lam C, Worrall CM, MaCurdy TE, Kelman JA

Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare data.

Pharmacoepidemiology and drug safety. 2014;23(9):911-7

Agarwal N, Cherascu B

Concomitant acral necrosis and haemolytic uraemic syndrome following ingestion of quinine.

Journal of postgraduate medicine. 2002;48(3):197-8